Terms: = Breast cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Treatment
1872 results:
1. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of drug release efficiency and antibacterial property of a pH-responsive dextran-based silver nanocomposite hydrogel.
Luanda A; Manohar M; Charyulu RN; Badalamoole V
Int J Biol Macromol; 2024 May; 268(Pt 2):131783. PubMed ID: 38657933
[TBL] [Abstract] [Full Text] [Related]
3. Improving quality of life after breast cancer: a comparison of two microsurgical treatment options for breast cancer-related lymphedema (BCRL).
Seidenstuecker K; Fertsch S; Ghazaleh AA; Fabi A; Stoffel J; Bukowiecki J; Wolter A; Aghlmandi S; Nadella A; Halbeisen FS; Andree C; Haug MD; Schaefer DJ; Handschin TM; Kappos EA
Clin Exp Med; 2024 Apr; 24(1):82. PubMed ID: 38653874
[TBL] [Abstract] [Full Text] [Related]
4. Exploring the association of POSTN
Lin S; Zhou M; Cheng L; Shuai Z; Zhao M; Jie R; Wan Q; Peng F; Ding S
Int J Biol Macromol; 2024 May; 268(Pt 1):131560. PubMed ID: 38631570
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer.
Bagheri M; Mohamed GA; Mohamed Saleem MA; Ognjenovic NB; Lu H; Kolling FW; Wilkins OM; Das S; LaCroix IS; Nagaraj SH; Muller KE; Gerber SA; Miller TW; Pattabiraman DR
Cell Rep Med; 2024 Apr; 5(4):101504. PubMed ID: 38593809
[TBL] [Abstract] [Full Text] [Related]
6. Single-cell transcriptomics reveals the intra-tumoral heterogeneity and SQSTM1/P62 and Wnt/β-catenin mediated epithelial to mesenchymal transition and stemness of triple-negative breast cancer.
Shome R; Sen P; Sarkar S; Ghosh SS
Exp Cell Res; 2024 May; 438(1):114032. PubMed ID: 38583856
[TBL] [Abstract] [Full Text] [Related]
7. Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy.
Lin D; Sturgeon KM; Muscat JE; Zhou S; Hobkirk AL; O'Brien KM; Sandler DP; Thompson CL
Breast Cancer; 2024 May; 31(3):519-528. PubMed ID: 38564089
[TBL] [Abstract] [Full Text] [Related]
8. Withaferin A alters the expression of microRNAs 146a-5p and 34a-5p and associated hub genes in MDA-MB-231 cells.
Shuaib M; Chaudhri S; Kumar S
Biomol Concepts; 2024 Jan; 15(1):. PubMed ID: 38525814
[TBL] [Abstract] [Full Text] [Related]
9. Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center.
Loggie J; Barnes PJ; Carter MD; Rayson D; Bethune GC
Breast; 2024 Jun; 75():103715. PubMed ID: 38520994
[TBL] [Abstract] [Full Text] [Related]
10. Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer.
Vo K; Ladbury C; Yoon S; Bazan J; Glaser S; Amini A
Breast Cancer; 2024 May; 31(3):485-495. PubMed ID: 38507145
[TBL] [Abstract] [Full Text] [Related]
11. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
[TBL] [Abstract] [Full Text] [Related]
12. [Research Status and Trend of Screening for Women's Common Diseases in China].
Fan ZX; Yan MY; Pei CY; Lei QR; Ma J; Liu YL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Feb; 46(1):33-38. PubMed ID: 38433628
[TBL] [Abstract] [Full Text] [Related]
13. Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative breast cancer.
Wang C; Shi Q; Zhang G; Wu X; Yan W; Wan A; Xiong S; Yuan L; Tian H; Ma D; Jiang J; Qi X; Zhang Y
Oncologist; 2024 May; 29(5):e635-e642. PubMed ID: 38431781
[TBL] [Abstract] [Full Text] [Related]
14. The Association Between Mammography Screening Frequency and breast cancer treatment and Outcomes: A Retrospective Cohort Study.
Liu Y; Gordon AS; Eleff M; Barron JJ; Chi WC
J Breast Imaging; 2023 Feb; 5(1):21-29. PubMed ID: 38416960
[TBL] [Abstract] [Full Text] [Related]
15. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the treatment of Triple-Negative breast cancer.
Jaradat SK; Ayoub NM; Al Sharie AH; Aldaod JM
Technol Cancer Res Treat; 2024; 23():15330338241234780. PubMed ID: 38389413
[TBL] [Abstract] [Full Text] [Related]
16. Simultaneous evaluation of brain metastasis and thoracic cancer using semiconductor
Kaneko K; Nagao M; Ueda K; Yamamoto A; Sakai S
Ann Nucl Med; 2024 Apr; 38(4):278-287. PubMed ID: 38386272
[TBL] [Abstract] [Full Text] [Related]
17. Eligibility criteria for using menopausal hormone therapy in breast cancer survivors: a safety report based on a systematic review and meta-analysis.
Coronado PJ; Gómez A; Iglesias E; Fasero M; Baquedano L; Sánchez S; Ramírez-Polo I; de la Viuda E; Otero B; Llaneza P; Mendoza N; Lubián DM;
Menopause; 2024 Mar; 31(3):234-242. PubMed ID: 38385734
[TBL] [Abstract] [Full Text] [Related]
18. The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.
Sato H; Ito T; Hayashi T; Kitano S; Erdjument-Bromage H; Bott MJ; Toyooka S; Zauderer M; Ladanyi M
Oncogene; 2024 Apr; 43(15):1087-1097. PubMed ID: 38383726
[TBL] [Abstract] [Full Text] [Related]
19. US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative,
Shah M; Lingam H; Gao X; Gittleman H; Fiero MH; Krol D; Biel N; Ricks TK; Fu W; Hamed S; Li F; Sun JJ; Fan J; Schuck R; Grimstein M; Tang L; Kalavar S; Abukhdeir A; Pathak A; Ghosh S; Bulatao I; Tilley A; Pierce WF; Mixter BD; Tang S; Pazdur R; Kluetz P; Amiri-Kordestani L
J Clin Oncol; 2024 Apr; 42(10):1193-1201. PubMed ID: 38381994
[TBL] [Abstract] [Full Text] [Related]
20. Preoperative factors that predict pathologic nodal involvement in early-stage HER2+ breast cancer: selecting cT1cN0 patients for treatment with neoadjuvant chemotherapy versus upfront surgery.
Faleh S; Prakash I; Salehi A; Khan H; Basik M; Boileau JF; Tejera D; Panet F; Martel K; Meterissian S; Wong SM
Breast Cancer Res Treat; 2024 Jun; 205(2):303-312. PubMed ID: 38381275
[TBL] [Abstract] [Full Text] [Related]
[Next]
